RXi Pharmaceuticals Presents Updated NeuVax Data At ASCO

RXi Pharmaceuticals Corporation RXII developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, will be presenting data from the NeuVax Phase II adjuvant breast cancer clinical trial at the 2011 annual meeting of The American Society of Clinical Oncology in Chicago.